Action NXL NEXALIN TECHNOLOGY, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Nexalin Technology, Inc.

Actions

NXL

US65345B2016

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/06/2024 		Varia. 5j. Varia. 1 janv.
2,73 USD +20,80 % Graphique intraday de Nexalin Technology, Inc. +162,50 % +574,41 %
26/06 Nexalin Technology annonce les résultats positifs d'une étude clinique sur le trouble dépressif majeur et la publication des résultats de l'essai clinique dans une revue scientifique de premier plan CI
18/06 Nexalin Technology annonce que l'Agence brésilienne de réglementation de la santé a approuvé la vente du dispositif de neurostimulation Gen-2 de 15 mA de Nexalin CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
Nexalin Technology : unveils positive results of clinical study for Gen-2 tACS device
Nexalin Technology Files $5.6 Million Shelf Registration
Nexalin Technology CEO Provides Letter to Shareholders
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NXL
  4. Actualités Nexalin Technology, Inc.
  5. Autres langues